UBS Group Reiterates $45.00 Price Target for Pfizer (NYSE:PFE)
UBS Group Reiterates $45.00 Price Target for Pfizer (NYSE:PFE)
Health Care
Wells Fargo Lowered Pfizer(NYSE:PFE) Price Target from $50.00 to $44.00
Wells Fargo Lowered Pfizer(NYSE:PFE) Price Target from $50.00 to $44.00 with an “equal weight” rating。
Pfizer Inc. (NYSE:PFE) to Post Q1 2023 Earnings of $0.72 Per Share, Jefferies Financial Group Forecasts
Jefferies Financial Group lowered their Q1 2023 earnings estimates for shares of Pfizer in a note issued to investors on Friday, March 17th. Jefferies Financial Group analyst A. Tewari now anticipates that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.78. Jefferies Financial Group … Read more
Amgen (NASDAQ:AMGN) announced 450 job cuts for the second time this year
US drugmaker Amgen (NASDAQ:AMGN) said it would lay off about 450 further jobs, less than 2 percent of its workforce, citing drug price pressures, as well as the impact of high inflation. At the end of January, the company announced 300 layoffs.
JPMorgan Give Pfizer (NYSE:PFE) a $45.00 Price Target
JPMorgan Chase & Co. Analysts Give Pfizer (NYSE:PFE) a $45.00 Price Target
Pfizer (NYSE:PFE) Sees 2023 Adj. EPS $3.25-$3.45, Below the FactSet Consensus $4.34
Pfizer (NYSE:PFE) Sees 2023 Adj. EPS $3.25-$3.45, Below the FactSet Consensus $4.34
Pfizer (NYSE:PFE) Q4 2022 Adj. EPS of $1.14, Beats the FactSet Consensus $1.05
Pfizer (NYSE:PFE) Q4 2022 Adj. EPS Rose to $1.14 From 79 Cents a Year Ago, Beats the FactSet Consensus $1.05。
Pfizer(NYSE:PFE) Q4 2022 Revenue of $24.29 Billion, Below the FactSet Consensus $24.38 Bln
Pfizer (NYSE:PFE) Q4 2022 Revenue Rose 1.9% to $24.29 Billion, Below the FactSet Consensus $24.38 Bln。
Pfizer (NYSE:PFE) reported Q4 2022 Revenues of $24.3 Billion，update 2023 financial guidance
January 31, 2023 — Pfizer Inc. (NYSE:PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Pfizer Inc. (NYSE:PFE) reported Q4 adjusted earnings of $1.14 per diluted share, up from $0.79 a year earlier. Analysts polled by Capital IQ expected $1.04. Revenue for the quarter was $24.29 billion, up from … Read more
Pfizer (NYSE:PFE) to acquire Seagen (NASDAQ:SGEN) for $43 billion
Pfizer Inc (NYSE:PFE) said Monday it agreed to buy biotech company Seagen Inc (NASDAQ:SGEN) for $43 billion to bolster its cancer treatment program. The New York-based drugmaker said it would pay $229 a share in cash, a nearly 33 percent premium to Seagen’s closing price of $172.61 on Friday. Seagen is headquartered in Bothel, Washington. … Read more